Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dick Jonathan, Nagai Kei, Koo Yuk Cheong Daniel, Le Anne Cao, Tan Diana Shu Yee, Alikhan Maliha, Monk Julie, Ooi Joshua Daniel, Kitching A Richard, Gan Poh-Yi
Аннотация
BACKGROUND AND HYPOTHESIS: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a major cause of glomerulonephritis (GN) and kidney failure and current therapies are often limited by significant toxicity and limitations. Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance, and their dysfunction has been implicated in AAV pathogenesis. Low dose interleukin-2 (IL-2) has emerged as a promising strategy to selectively expand Tregs and restore immune balance in several autoimmune diseases. However, low dose IL-2's therapeutic potential in AAV remains unclear, warranting further investigation into its immunoregulatory effects in experimental AAV models.
METHODS: We tested the therapeutic efficacy of low dose IL-2 therapy (25 000 international units/day) in an experimental murine model of AAV, specifically anti-myeloperoxidase (MPO) GN, using C57BL/6J mice. Both passive and active models of anti-MPO GN were used to assess IL-2's effects across different disease settings.
RESULTS: In GN induced by passive transfer of anti-MPO antibodies, low dose IL-2 increased intrarenal Treg numbers, limited macrophage recruitment, and reduced macrophage pro-inflammatory phenotype in kidneys, demonstrating anti-inflammatory effects on innate immunity. However, these immunological changes did not translate into improvement in kidney injury. In T-cell mediated active anti-MPO GN induced by MPO immunization and triggered by anti-glomerular basement membrane globulin, preventative IL-2 therapy increased splenic Tregs, attenuated anti-MPO-specific Th1/Th17 responses and limited structural and functional kidney injury. In established autoimmunity, mice treated with low dose IL-2 from 12 days after MPO immunization also expanded splenic Tregs. However, effector T-cell responses were also enhanced and glomerular injury was increased. To more specifically target Tregs and minimize low dose IL-2's potential to promote effector leukocytes, we administered IL-2 conjugated to an anti-IL-2 monoclonal antibody (IL-2/anti-IL-2 immune complex). Although IL-2/anti-IL-2 treatment increased Treg frequency in mice with established anti-MPO autoimmunity, it also paradoxically amplified anti-MPO T-cell effector responses and worsened glomerulonephritis.
CONCLUSION: In experimental anti-MPO GN, low dose IL-2 therapy has context specific effects on cellular and humoral immunity, and the potential for it to promote T effector responses in established autoimmunity may limit its utility in this condition.
METHODS: We tested the therapeutic efficacy of low dose IL-2 therapy (25 000 international units/day) in an experimental murine model of AAV, specifically anti-myeloperoxidase (MPO) GN, using C57BL/6J mice. Both passive and active models of anti-MPO GN were used to assess IL-2's effects across different disease settings.
RESULTS: In GN induced by passive transfer of anti-MPO antibodies, low dose IL-2 increased intrarenal Treg numbers, limited macrophage recruitment, and reduced macrophage pro-inflammatory phenotype in kidneys, demonstrating anti-inflammatory effects on innate immunity. However, these immunological changes did not translate into improvement in kidney injury. In T-cell mediated active anti-MPO GN induced by MPO immunization and triggered by anti-glomerular basement membrane globulin, preventative IL-2 therapy increased splenic Tregs, attenuated anti-MPO-specific Th1/Th17 responses and limited structural and functional kidney injury. In established autoimmunity, mice treated with low dose IL-2 from 12 days after MPO immunization also expanded splenic Tregs. However, effector T-cell responses were also enhanced and glomerular injury was increased. To more specifically target Tregs and minimize low dose IL-2's potential to promote effector leukocytes, we administered IL-2 conjugated to an anti-IL-2 monoclonal antibody (IL-2/anti-IL-2 immune complex). Although IL-2/anti-IL-2 treatment increased Treg frequency in mice with established anti-MPO autoimmunity, it also paradoxically amplified anti-MPO T-cell effector responses and worsened glomerulonephritis.
CONCLUSION: In experimental anti-MPO GN, low dose IL-2 therapy has context specific effects on cellular and humoral immunity, and the potential for it to promote T effector responses in established autoimmunity may limit its utility in this condition.